Last Updated: November 13, 2026

Litigation Details for CELGENE CORPORATION v. LOTUS PHARMACEUTICAL CO., LTD. (D.N.J. 2018)

« Back to Dashboard


CELGENE CORPORATION v. LOTUS PHARMACEUTICAL CO., LTD. (D.N.J. 2018)

Docket 2:18-cv-11518 Date Filed 2018-07-10
Court District Court, D. New Jersey Date Terminated 2019-03-29
Cause 15:1126 Patent Infringement Assigned To Susan Davis Wigenton
Jury Demand None Referred To Leda Dunn Wettre
Parties LOTUS PHARMACEUTICAL CO., LTD.
Patents 6,315,720; 6,561,977; 6,755,784; 7,189,740; 7,465,800; 7,855,217; 7,968,569; 8,315,886; 8,404,717; 8,530,498; 8,626,531; 8,648,095; 9,056,120; 9,101,621; 9,101,622
Attorneys DAVID LEIGH MOSES
Firms Lerner David Littenberg Krumholz and Mentlik LLP
Link to Docket External link to docket
Small Molecule Drugs cited in CELGENE CORPORATION v. LOTUS PHARMACEUTICAL CO., LTD.
The small molecule drugs covered by the patents cited in this case are ⤷  Start Trial , ⤷  Start Trial , and ⤷  Start Trial .

Details for CELGENE CORPORATION v. LOTUS PHARMACEUTICAL CO., LTD. (D.N.J. 2018)

Date Filed Document No. Description Snippet Link To Document
2018-07-10 External link to document
2018-07-10 1 Complaint United States Patent Nos. 5,635,517 (the “’517 patent”), 6,315,720 (the “’720 patent”), 6,561,977 (the… patent”), and 8,431,598 (the “’598 patent”), all owned by Celgene (collectively, “the patents-in- …(the “’977 patent”), 6,755,784 (the “’784 patent”), 7,189,740 (the “’740 patent”), 7,465,800 (the “’800…’800 patent”), 7,855,217 (the “’217 patent”), 7,968,569 (the “’569 patent”), 8,315,886 (the “’886 patent…,717 (the “’717 patent”), 8,530,498 (the “’498 patent”), 8,626,531 (the “’531 patent”), 8,648,095 (the External link to document
2018-07-10 40 Judgment, the term Patents-in-Suit shall mean U.S. Patent Nos. 5.635,517; 6,3 15,720; 6,561,977; 6,755,784; … the term “Patents—in—Suit” shall mean U.S. Patent Nos. 5.635,517; 6,3 15,720; 6,561,977; 6,755,784… 4. Until expiration of the Patents.ineSuit, Lotus, including any of Its successors…parties in connection with any infringement of the Patents-in-Suit by any such third panics in connection…C.F.R. § 31 4.94(a)( 12) with respect to the Patents-in-Suit. 9. Nothing External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.